Genebox Female Cancer Susceptibility Panel — 21 Provider-Listed Conditions

Genebox

Published reference

An optional cancer susceptibility testing panel within a broader genetic assessment. The provider lists 21 conditions for women. Confirm the testing arrangements and eligibility requirements with the provider.

Price informationPrice to be confirmedConfirm current scope and fees with the provider.

Technology: The broader assessment is described as using genetic chip technology. Confirm the exact technology and test configuration for this optional panel with the provider.

The provider lists 21 conditions within the genetic susceptibility assessment. The complete list appears below. This scope does not establish the ability to diagnose or rule out cancer.

View the broader genetic assessment →

Conditions listed for this panel · 21

Lung cancer
Pancreatic cancer
Colorectal cancer
Gastric cancer
Esophageal cancer
Liver cancer
Cervical cancer
Ovarian cancer
Breast cancer
Thyroid cancer
Melanoma
Basal cell carcinoma
Glioma
Laryngeal cancer
Oral cancer
Chronic lymphocytic leukemia
Lymphoma
Kidney cancer
Bladder cancer
Uterine fibroids
Multiple myeloma

Details to confirm before arranging

Current availability

Current purchase or testing availability has not been confirmed

Sample and collection

Confirm the sample type and collection method with the testing provider

Report turnaround

A separate report turnaround time is not stated for this optional panel; confirm it with the provider.

Report language

English-language report availability is not stated and must be confirmed with the provider

Eligibility of foreign customers

Eligibility of foreign customers must be confirmed with the provider

Before arranging this item

This is an optional panel within a broader assessment. Separate purchase has not been confirmed.

The CNY 3,998 price shown for the broader assessment is not a confirmed quotation for this optional panel.

This panel concerns genetic susceptibility information. It does not diagnose an existing cancer or determine whether cancer is currently present.

The broader assessment’s product name does not establish whole-genome sequencing (WGS), and it does not establish that this panel is a clinical sequencing test.

'Comprehensive screening' is the provider's product wording. It does not establish coverage of every tumor or the ability to diagnose or rule out all cancers.

The provider's 21 listed conditions include uterine fibroids. The list must not be described as 21 malignant cancers.

The item name or bundle description and related content have been checked against the provider’s public source. This page is a consultation reference. Current purchase or testing availability, prices and eligibility still require confirmation with the provider.